Antibody-drug conjugates (ADCs) have emerged as a significant platform for precision oncology, demonstrating remarkable efficacy in various solid tumors in recent years. With ongoing innovations in target selection and linker technology, the development of ADCs for the treatment of metastatic castration-resistant prostate cancer (mCRPC) has also made significant strides. This article systematically reviews the latest … Read more
I recently read a great review that coincides with some recent advancements in ADCs, so I decided to summarize and learn from it. ADCs are a key milestone in the evolution of traditional drugs into precision-targeted therapies.Currently, 19 ADCs have been approved globally (including 2 that have been withdrawn), and over 300 ADCs are in … Read more
I recently read a great review that coincides with some recent advancements in ADCs, so I decided to summarize and learn from it. ADCs are a key milestone in the evolution from traditional drugs to precision-targeted therapies.Currently, 19 ADCs have been approved globally (including 2 that have been withdrawn), and over 300 ADCs are in … Read more
Introduction Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (brand name: Mylotarg)) was approved for the treatment of CD33-positive acute … Read more
Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative approach in cancer treatment, due to their potential for targeted therapy, fewer side effects, broader application, and higher therapeutic index compared to traditional chemotherapy.While ADCs initially focused on hematological malignancies, there has been a clear shift towards solid tumor treatment, with approximately 90% of ADC trials … Read more
Click the blue text above to follow us Editor’s Note: With their unique mechanisms of action and powerful efficacy, Antibody-Drug Conjugates (ADCs) have become indispensable treatment methods for various solid tumors and hematological cancers, such as breast cancer. The core component that determines the efficacy of ADCs is undoubtedly the payload. Different payloads exhibit significant … Read more